Background. Artemisinin-based combination therapy is the first-line treatment for uncomplicated falciparum malaria. This study assessed the antimalarial efficacy and safety of a combination of 150 mg of arterolane maleate and 750 mg of piperaquine phosphate (AM-PQP) in comparison to Coartem (artemether and lumefantrine) in patients with acute uncomplicated P. falciparum malaria.
that is easy to synthesize. Any shortage of raw ingredients required for pharmaceutical manufacturing will not affect the supply of this synthetic drug [4] . In a phase II study of 50 mg, 100 mg, and 200 mg oral doses of AM administered once daily for 7 days in uncomplicated falciparum malaria, median parasite clearance times (PCTs) of 31.2 hours and 31.5 hours were observed at 100 mg and 200 mg, respectively [5] . In the current study, we assessed the antimalarial efficacy and safety of a combination of 150 mg of AM and 750 mg of PQP administered orally, once daily for 3 days, in comparison to the standard sixdose regimen of Coartem (artemether-lumefantrine) in patients with acute uncomplicated falciparum malaria.
METHODS

Study Design
A randomized, open-label, multicentric study was conducted at 3 sites in India and 1 site in Thailand. Approvals from the Independent Ethics Committee(s)/Institutional Review Board(s; IECs/IRBs) and the respective national regulatory authorities were obtained for the study.
Patients
The patients were enrolled in the study if they consented to participate and met the inclusion criteria: age >12 to 65 years, both genders; monoinfection with P. falciparum; asexual parasite densities 1000-100 000/µL; fever (axillary temperature ≥37.5°C or oral ≥38°C); weight ≥35 kg and hemoglobin (Hb) ≥8 g/dL; female patients of child-bearing potential were enrolled if they were non-lactating, agreed to practice contraception during the study period, and were willing to be followed up for 28 days.
Randomization
Randomization numbers were allocated in an ascending consecutive order within each site based on a computer-generated randomization schedule prepared a priori. A permuted block scheme was used with undisclosed block sizes. Patients were randomized in a 2:1 ratio for the AM-PQP and Coartem arms, respectively, to ensure a larger safety database for the test product. Patients who discontinued early for any reason were not replaced.
Treatment
Patients were hospitalized, and AM and PQP were coadministered as a single daily dose for 3 consecutive days. Subsequent study medication was administered within 24 hours (±4 hours) of the initial dose. A 6-dose treatment with Coartem (FDC (fixed-dose combination) of artemether-lumefantrine) as a single dose of 4 tablets was administered at the time of initial diagnosis-4 tablets after approximately 8 hours and then four tablets twice daily on each of the following 2 days.
Patients received the test drug irrespective of meals; the reference product was, however, administered with milk or a fatty meal according to the prescribing information. The patients were discharged after the completion of 3 days of treatment and thereafter were followed up on days 7, 14, 21 and 28.
Assessments
Physical examination, including an assessment of vital signs and clinical signs and symptoms, was performed at the time of screening. These assessments were repeated on days 1, 2, 3, 7, 14, 21, 28 and on any unscheduled visit. Body temperature (in°C) was recorded at screening, pre-dose on day 0, and at 6-hour intervals for at least 48 hours following the first dose of study medication or until temperature remained normal for at least 24 hours and on all follow-up days.
The parasitological assessments were performed according to WHO guidelines at all centers [6] . Giemsa-stained blood smears were prepared from finger prick samples at screening, at 6-hour intervals during hospitalization, and at all follow-up visits. Asexual and sexual parasites were counted. Blood was also collected on 3MM filter paper (Whatman) for polymerase chain reaction (PCR) analysis prior to study medication administration on day 0 and on any other day if a patient spontaneously returned with fever. Genotyping by PCR analysis was conducted at a central laboratory at NIMR, New Delhi, for those patients whose parasitemia reappeared after initial clearance. Three polymorphic genetic markers, msp1, msp2 and glurp, were used to distinguish recrudescence from new infection [7] . The quality controlled procedure was conducted for randomly selected patients by an independent microscopist to confirm the eligibility of the examined patients for entry into the trial and also to confirm the efficacy outcome.
Laboratory evaluations for safety [hematology, biochemistry, and urinalysis (dipstick)] were performed at screening, on Days 2 and 28, and any other day if a patient spontaneously returned with fever. A urine pregnancy test (UPT) was performed at screening and on Days 14 and 28 on all female patients of childbearing potential, including females who were <1 year post-menopausal or who had not had a hysterectomy. In the event of a premature withdrawal from the study, the UPT was repeated.
A standard 12-lead ECG was performed at screening and between 2 and 4 hours after the last dose on day 2. The 12-lead ECG was repeated on day 28 or earlier if any abnormal recording was observed on day 2 or at any interim visit if clinically indicated.
Blood for the pharmacokinetic analysis was sampled only for patients randomized to AM-PQP. Maximum plasma drug concentrations (Cmax), time of occurrence of Cmax (Tmax), area under plasma concentration-time curves (AUC), and half-life (t ½ ) for AM and PQP were calculated from 15 patients assigned to intensive sampling until day 2. Sparse sampling was done from the rest of the patients enrolled for the AM-PQP treatment to calculate the population pharmacokinetics.
The criteria for defining clinically significant laboratory abnormalities or any worsening of or appearance of new signs/ symptoms from the earlier visit was based on the CTCAE (Common Terminology Criteria for Adverse Events) version 3 grading for determining the severity of adverse events (AEs). Any clinically significant abnormal laboratory result was followed until resolution, until it became stable, or until it could be explained by another known cause (eg, a concurrent condition or medication), making further tests unwarranted.
Statistical Analysis
Sample size calculation was based on an anticipated response rate of 95% for the primary end point, a 95% CI with ± 5% margin of error and an allocation ratio of 2:1 (AM-PQP: Coartem). Descriptive statistics were used to summarize baseline values. The efficacy parameter was analyzed using the Cochrane-Mantel-Haenszel test and logistic regression for both ITT and PP populations. Time taken to clear parasites, PCT, and time taken for fever clearance (FCT) in each group were estimated using a Kaplan-Meier graph followed by group comparisons using log-rank and Wilcoxon tests. The hazard ratio (AM-PQP: Coartem) for these parameters were estimated using the Cox proportional hazard model. Patients with incomplete follow-up times were censored at day 28 and were considered as failures in the ITT analysis. The safety evaluations were performed using summary statistics.
RESULTS
This study was conducted between November 2007 and June 2008. A total of 240 patients (intent-to-treat population ITT) were randomized to receive either AM-PQP (160 patients) or Coartem (80 patients). Initially, 229 patients were included in the Per-Protocol (PP) population. Six patients were lost to follow-up, 1 withdrew consent, and 2 patients at a Jamshedpur site were withdrawn because of a fire-related incident that resulted in the exposure of their AM-PQP medication to high temperatures. One patient treated with Coartem was withdrawn, as the patient had experienced an episode of "malena and inability to pass urine" that was labeled as a Serious Adverse Event by the investigator. After consultation with the sponsor, another patient who received the initial dose of Coartem was taken out of the trial by the investigator for a protocol deviation, as he had wrongly been included (Hb <8 gm/dL). Another patient treated with Coartem experienced a recurrence of parasitemia (treatment failure) at the Bangkok site and was included in the per protocol population (PP; Figure 1 ). No vivax malaria or mixed infection cases were reported in either of the arms during the study.
Demographic Characteristics
The demographic and baseline characteristics were comparable in both groups, except that there was a marginally significant (P = .0299) higher prevalence of males in the test regimen (Table 1) , which was considered incidental.
Parasitological and Clinical Responses
The primary endpoint analysis was the PCR-corrected ACPR (adequate clinical and parasitologic response) on day 28 (cure rate). A total of 151 of 160 patients in the AM-PQP arm and 77 of 80 patients in the Coartem arm completed the study. The cure rates were 94.4% and 96.3%, for the AM-PQP and Coartem populations, respectively (ITT; Table 2 ) and 100% (151/151) and 98.7% (77/78) for the AM-PQP and Coartem populations, respectively, in the PP population.
No difference was observed in the median PCT (30 hours) or FCT (24 hours) for both treatments (Tables 3 and 4 ; Figure 2 ).
Gametocyte Carriage
Baseline median gametocyte counts were slightly higher for the patients treated with AM-PQP (181.4/µL) than for patients treated with Coartem (113/µL). Among them, a 0 count at baseline was noted for 77.5% of patients treated with AM-PQP and 83.8% of those treated with Coartem. With both treatments, the median values of gametocyte counts decreased by day 2. On day 28 of the study, 148 (98%) patients treated with AM-PQP and 100% (78/78) treated with the comparator achieved a 0 gametocyte count.
Electrocardiographic Changes
The mean change in QTc interval from the baseline until day 2 in patients treated with AM-PQP and Coartem was recorded as 13.4 msec and 7.1 msec, respectively. Although the observed change was slightly higher for those treated with AM-PQP, it was not significant. Two patients treated with AM-PQP and 1 treated with Coartem had a QTc(F) >500 msec on day 2. Eight patients in the AM-PQP arm and 4 in the Coartem arm experienced a QTc(F) >60 msec on day 2 from baseline. None of these findings resulted in patients' discontinuation from the trial.
Pharmacokinetics
The pharmacokinetic results indicate that the C max , AUC 0-24 and AUC 4pts on day 2 of patients receiving arterolane were 1.24-, 1.34-and 1.36-fold, respectively. The higher exposure values on day 2 are attributed to the patients becoming aparasitemic. Piperaquine exposure increased on day 2 following multiple dosing as Clinical Trial of AM-PQP for Malaria • CID 2012:55 (1 September) • 665 compared to exposure of the drug when it was administered on day 0. The mean increase in C max , AUC 0-24 and AUC 4pts of piperaquine on day 2 was 2.43-, 3.31-and 3.19-fold, respectively. It is expected that the drug will accumulate when multiple doses of piperaquine are administered due to its long elimination half-life (Table 5) .
The plasma concentrations achieved on day 2 corroborate with the approximate 2-fold increase in exposures obtained in an earlier study when patients followed a 7-day treatment with AM (unpublished data on file). There was no change in the t max and t 1/2 of arterolane. Considering the long terminal halflife of piperaquine, it was not possible to reliably estimate its t 1/2 in this study with the limited duration of sampling (Table 5) .
AE Incidence and Types
The overall incidences of treatment-emergent AEs were comparable. A total of 206 patients out of the 240 (85.8%) experienced at least one AE during the course of the study. A majority of the AEs were related to the blood and lymphatic system. Eosinophilia (37.5%) was the most common AE experienced by patients belonging to either of the groups. Neutropenia, hyperkalemia, and anemia were among the other commonly reported AEs, along with thrombocytopenia, Figure 1 . Treatment allocation and outcome among patients. Abbreviations: AM, arterolane maleate; AST, aspartate aminotransferase; C, completed; D, discontinued; PQP, piperaquine phosphate; SAE, Serious Adverse Event.
lymphocytosis, leukopenia, hyponatremia, hyperbilirubinemia, hypoglycemia, and an increase in liver enzymes and hypoalbuminemia that was observed in both treatment groups (Table 6 ). The incidence of clinical AEs related to the gastrointestinal system, such as vomiting, dyspepsia and pain in the upper abdomen, was similar in patients who received either the AM-PQP or the Coartem (Table 7) .
Two severe AEs were reported. A 45-year-old male patient receiving treatment with Coartem complained of having not passed urine for a 24-hour period on day 1. The patient also gave a history of passing black-coloured stool since 2 days prior to his admission. On clinical examination, the patient had appeared "toxic" although his vital signs and other body systems were normal. Fearing a possible progression to severe malaria, the investigator withdrew the patient from the study and administered rescue therapy. The patient was discharged in a healthy state. Another 30-year-old male patient treated with AM-PQP experienced an episode of hyperventilation syndrome on day 3. The patient recovered and successfully completed the study. In both the cases, the investigator determined that the adverse reactions were not related to the study medication. None of the AEs recorded had a definite relationship to the study medication or led to the premature withdrawal of a patient from the study.
DISCUSSION
In this study, both Coartem and AM-PQP were well tolerated and effective in clearing parasitemia in patients suffering from uncomplicated falciparum malaria. A 6-dose regimen for Coartem is the standard antimalarial treatment for uncomplicated P. falciparum and mixed infections and has been globally adopted as a first-line antimalarial [8] .
The PCR-corrected ACPR for AM-PQP was similar to Coartem. The secondary outcomes, such as PCT, FCT and gametocyte clearance, were also comparable. Earlier trials with Coartem involving both adult and pediatric populations obtained median PCT values that ranged from 24-48 hours, which are comparable with the present study [8] . AM is a rapid, short-acting drug that is effective against all parasite blood stages, while PQP is a slow, long-acting drug that kills residual parasites [9] . Hence, the combination provides antimalarial activity at different time windows that will prevent the emergence of resistance to either drug. Moreover, the mechanism of action of arterolane is slightly different from artemisinins [10] . There were no treatment failures in the AM-PQP arm and no recrudescence or new infection observed in the study. It was observed during the initial visits that both regimens exhibited effective gametocidal activity. AM-PQP appears to have gametocidal activity comparable to Coartem. Mens et al observed that the microscopic detection of gametocytes in blood slides was subject to fluctuations, which is probably due to the fact that gametocytes circulate at low levels. Therefore, there is an urgent need to develop and validate more sensitive and specific assays [11] . In the present study, gametocytes persisted during the course of follow-up visits in patients treated with either of the drugs. Persistence of gametocytes has been reported after treatment with 5 artemisinin combination regimens, and a 12-fold lower gametocyte carriage was reported when primaquine was added to ACTs [12] . However, there has been a recent challenge to the traditional belief that it is important to obtain gametocyte clearance during treatment due to its ability to interrupt the parasite transmission to the vector [13] .
The overall incidence of treatment-emergent adverse events was comparable in the 2 treatment arms-86.3% in the AM-PQP arm vs 85% in the Coartem arm. In various studies of Quartile estimates and 95% confidence intervals calculated using the Kaplan-Meier method.
Abbreviations: AM, arterolane maleate; PQP, piperaquine phosphate. a P value compares the time-to-parasite-clearance curves of the treatment groups using the log-rank test and the Wilcoxon-Gehan test.
b Hazard ratio calculated using a Cox proportional hazard model. Parasite clearance time is defined as the time in hours from the initiation of therapy until the first of two successive parasite-negative smears were obtained. Quartile estimates and 95% confidence intervals calculated using the Kaplan-Meier method.
Abbreviations: AM, arterolane maleate; NE, not estimated; PQP, piperaquine phosphate. a P value compares the time-to-fever-clearance curves of the treatment groups using the log-rank test and the Wilcoxon-Gehan test.
b Hazard ratio calculated using a Cox proportional hazard model. Fever clearance time is defined as the time from first dosing until the disappearance of fever (<37.5°C) for at least 24 hours.
artemether-lumefantrine treatment for malaria, anemia and thrombocytopenia were frequently recorded at baseline but returned to normal or improved considerably with the resolution of disease [14] .
Among the clinical AEs, incidences of nausea, vomiting, dyspepsia, upper abdominal pain, headache, asthenia, and dizziness were reported by similar numbers of patients in the 2 treatment arms. The safety data reported in earlier Coartem studies are similar to the data reported in the present study [8] . In a pooled analysis of the data from studies conducted in Thailand where monotherapy of either artemisinins (artesunate/artemether) or mefloquine was compared with safety information collected from patients exposed to a combination therapy of artesunate + mefloquine, the incidences of acute nausea, vomiting, anorexia, and dizziness were reported frequently in the ACT group [15] The incidences of nausea and vomiting during the three days of treatment with dihydroartemisinin-piperaquine ranged from 3.2% in Thailand to 9.9% in Rwanda [16] . Similarly, Ashley et al Figure 2 . Kaplan-Meier curve for parasite clearance time in the intent-to-treat population, by treatment group. The median time to parasite clearance was 30 hours in each group. Each circle represents a censored value. P = .8665, by the log-rank test. Abbreviations: AM, arterolane maleate; PQP, piperaquine phosphate. Schedule B: venous blood sample (2 mL) was collected at day 0: pre-dose, 3 hr and 6 hr post-dose, day 1 pre-dose; day 2: pre-dose, 3, 6 and 24 hours post-day 2 dose and at the time of follow-up visits on day 7, day 14, day 21 and day 28.
Abbreviations: AUC, area under plasma concentration-time curves; N, number of patients; GM, geometric mean. a Data of patients assigned to Schedule B sampling, remaining parameters are of Schedule A patients (2005) reported nausea in 9.4% of patients and vomiting in 5.9% of patients treated with dihydroartemisinin + piperaquine [17] . The incidence of headache observed with AM-PQP was less than that reported with similar once-daily administration of dihydroartemisinin-piperaquine in various studies [18, 19] . Decreasing hemoglobin and hematocrit levels, a characteristic of malaria, were observed on day 2. During subsequent followup, hemoglobin and hematocrit levels improved. Eosinophilia (38.1%) and neutropenia (31.3%) were the most common adverse events reported in the test arm. Variations in the eosinophil count during treatment with antimalarial drugs have been previously reported. The malaria patients experienced an increase in the eosinophil count between days 0 to 7, which then significantly declined from day 7 to day 14. Thereafter, eosinophils again progressively increased until day 28. This suggests that early eosinophilia is a part of a healthy immune response that facilitates full haematological recovery from malaria infection [13] . Malaria has also been known to cause margination of neutrophils, which is the reduction of the circulatory pool of neutrophils as the neutrophils shift to the "marginal" pool, an action that accounts for pseudoneutropenia to some extent [20] . Moreover, the neutropenia observed in the majority of the cases in the current trial was mild in severity. Hence, it cannot be ascertained whether these changes in eosinophil and neutrophil counts are due to either a drug or disease. QTc prolongation is a known class effect of many antimalarials, so the corrected QT interval (QTc) was part of the safety assessments. The appearance or worsening of morphological abnormalities as compared to baseline was not observed in either of the treatment arms. Such QT interval changes during treatment with antimalarial drugs are difficult to evaluate, as there are systematic differences between the presentation during the acute febrile phase and convalescence (usually on day 3 of treatment). At the initiation of anti-malaria therapy, patients are usually anxious, fasting, and febrile, with increased autonomic tones and an increased heart rate. In contrast, at convalescence, the patient is relaxed, fed, supine, and afebrile when the peak concentrations of the drugs are achieved in the blood [21] . It has been argued that this systematic reduction in sympathetic activity that accompanies recovery will lead to a consistent increase in the QT interval and should not be ascribed to antimalarial drug effects.
The available data support the evaluation of the drug combination AM-PQP in a larger population. In conclusion, AM-PQP is a safe and well-tolerated treatment for uncomplicated falciparum malaria. The combination is currently being evaluated in a multicentre, double-blind, randomized, controlled, phase III study in adult patients with acute, uncomplicated falciparum malaria that will compare the safety and efficacy of fixed-dose combination tablets. A total of 520 patients were enrolled until March 2012 from sites in Asia and Africa.
Notes
